Pages that link to "Q35117192"
Jump to navigation
Jump to search
The following pages link to Effect of empagliflozin monotherapy on postprandial glucose and 24-hour glucose variability in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, 4-week study (Q35117192):
Displaying 33 items.
- The EMPA-REG outcome study: critical appraisal and potential clinical implications (Q26748742) (← links)
- Differential pharmacology and clinical utility of empagliflozin in type 2 diabetes (Q26749281) (← links)
- Effects of sodium-glucose co-transporter 2 (SGLT2) inhibition on renal function and albuminuria in patients with type 2 diabetes: a systematic review and meta-analysis (Q32186373) (← links)
- Sodium-glucose Co-transporter 2 Inhibitors Reduce the Abdominal Visceral Fat Area and May Influence the Renal Function in Patients with Type 2 Diabetes (Q33619161) (← links)
- Safety and Tolerability of Empagliflozin in Patients with Type 2 Diabetes: Pooled Analysis of Phase I-III Clinical Trials. (Q33890770) (← links)
- The role of empagliflozin in the management of type 2 diabetes by patient profile (Q35592873) (← links)
- Safety, tolerability and effects on cardiometabolic risk factors of empagliflozin monotherapy in drug-naïve patients with type 2 diabetes: a double-blind extension of a Phase III randomized controlled trial (Q36402095) (← links)
- Effects of analogue insulin in multiple daily injection therapy of type 2 diabetes on postprandial glucose control and cardiac function compared to human insulin: a randomized controlled long-term study (Q36469075) (← links)
- Substantial Effects of Luseogliflozin Revealed by Analyzing Responses to Postprandial Hyperglycemia: Post Hoc Subanalyses of a Randomized Controlled Study (Q37080615) (← links)
- Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes (Q37325818) (← links)
- Sodium glucose transporter 2 (SGLT2) inhibition with empagliflozin improves cardiac diastolic function in a female rodent model of diabetes (Q37586729) (← links)
- An evidence-based practice-oriented review focusing on canagliflozin in the management of type 2 diabetes (Q37661798) (← links)
- Long-Term Efficacy and Safety of Empagliflozin Monotherapy in Drug-Naïve Patients with Type 2 Diabetes in Indian Subgroup: Results from a 76-week Extension Trial of Phase III, Double-Blind, Randomized Study (Q37721942) (← links)
- The effect of SGLT2 inhibitors on cardiovascular events and renal function. (Q38614488) (← links)
- The effect of empagliflozin on oxidative nucleic acid modifications in patients with type 2 diabetes: protocol for a randomised, double-blinded, placebo-controlled trial (Q38793748) (← links)
- Sodium-glucose co-transporter 2 inhibitors for type 2 diabetes mellitus: An overview for the primary care physician (Q38821464) (← links)
- Impact of empagliflozin in patients with diabetes and heart failure (Q38822815) (← links)
- Cardiovascular effects of anti-diabetes drugs (Q38857056) (← links)
- Sodium-glucose cotransporter 2 inhibition and health benefits: The Robin Hood effect (Q38978384) (← links)
- Rationale for treatment options for mealtime glucose control in patients with type 2 diabetes (Q39101008) (← links)
- SGLT-2 Inhibitors in Heart Failure: Implications for the Kidneys (Q39408236) (← links)
- Effects of luseogliflozin, a sodium-glucose co-transporter 2 inhibitor, on 24-h glucose variability assessed by continuous glucose monitoring in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, crossov (Q41154151) (← links)
- Early effects of sodium-glucose co-transporter 2 inhibitors in type 2 diabetes: study based on continuous glucose monitoring (Q41263234) (← links)
- Empagliflozin lessened cardiac injury and reduced visceral adipocyte hypertrophy in prediabetic rats with metabolic syndrome (Q41849079) (← links)
- Comparative effectiveness and safety of empagliflozin on cardiovascular mortality and morbidity in adults with type 2 diabetes. (Q47236288) (← links)
- Effects of Dapagliflozin on 24-Hour Glycemic Control in Patients with Type 2 Diabetes: A Randomized Controlled Trial (Q58709946) (← links)
- Comparative safety of the sodium glucose co-transporter 2 (SGLT2) inhibitors: a systematic review and meta-analysis (Q64230875) (← links)
- Empagliflozin as adjunct to insulin in Japanese participants with type 1 diabetes: Results of a 4-week, double-blind, randomized, placebo-controlled phase 2 trial (Q88688829) (← links)
- Systematic Review of Efficacy and Safety of Newer Antidiabetic Drugs Approved from 2013 to 2017 in Controlling HbA1c in Diabetes Patients (Q89314601) (← links)
- Effects of ipragliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the multicenter prospective intervention study (Q90154725) (← links)
- SGLT2 Inhibitors for Type 2 Diabetes Mellitus Treatment (Q91599044) (← links)
- Empagliflozin reduces blood pressure and uric acid in patients with type 2 diabetes mellitus: a systematic review and meta-analysis (Q93161781) (← links)
- Gender Differences in Cardiac Function Following Three-Month Administration of Tofogliflozin in Patients With Diabetes Mellitus (Q98736006) (← links)